ライフサイエンスコーパス: Cushing's disease

1 y challenging in patients with acromegaly or Cushing's disease.

2 g intramuscular pasireotide in patients with Cushing's disease.

3 ion, schizophrenia, Alzheimer's disease, and Cushing's disease.

4 hat are frequently observed in patients with Cushing's disease.

5 ng-term survival prospects for patients with Cushing's disease.

6 CYP11B1 is a promising drug target to manage Cushing's disease, a disorder arising from excessive cor

7 g) = 17; prolactinomas (PRL-secreting) = 11, Cushing's disease (ACTH-secreting) = 4, non-functional =

8 study, we randomly assigned 162 adults with Cushing's disease and a urinary free cortisol level of a

9 T studies that were done on 13 patients with Cushing's disease and compared the results with those ob

10 to anxiety-related behavior in patients with Cushing's disease and depression.

11 endocrine and psychiatric disorders, such as Cushing's disease and depression.

12 mpared mortality rates between patients with Cushing's disease and the general population, and expres

13 The molecular mechanisms leading to Cushing's disease are unclear.

14 concentration in about 40% of patients with Cushing's disease at month 7 and had a similar safety pr

15 ublications, were diagnosis and treatment of Cushing's disease, being cured of hypercortisolism for a

16 operty of LCI699 prompted its development in Cushing's disease, but limited more extensive clinical s

17 Cushing's disease, characterized by elevated plasma cort

18 ecreased, and clinical signs and symptoms of Cushing's disease diminished.

19 by bilateral laparoscopic adrenalectomy for Cushing's disease from 1994 to 2004.

20 entiating a pituitary source of excess ACTH (Cushing's disease) from an ectopic source is accomplishe

21 Patients with Cushing's disease had a significant reduction in cerebra

22 Cushing's disease is a rare debilitating endocrine disor

23 opic bilateral adrenalectomy for symptomatic Cushing's disease is a safe and effective treatment opti

24 Cushing's disease is associated with high morbidity and

25 d cerebral glucose metabolism we observed in Cushing's disease is attributable to increased glucocort

26 = 20), cortisol-producing adenomas (n = 13), Cushing's disease (n = 8), and others (n = 13).

27 suggesting that central obesity may reflect "Cushing's disease of the omentum".

28 as well normalization of urinary cortisol in Cushing's disease patients.

29 experience considerable improvement in their Cushing's disease symptoms, and their quality of life eq

30 ients undergoing bilateral adrenalectomy for Cushing's disease through either the anterior or posteri

31 urrent, or de-novo (non-surgical candidates) Cushing's disease who had a mean urinary free cortisol (

32 Patients with Cushing's disease who have been in remission for more th

33 ious treatment option for some patients with Cushing's disease who have persistent or recurrent disea

34 decrease in cortisol levels in patients with Cushing's disease who received pasireotide supports its